Zydus Lifesciences Ltd on Monday announced a licensing pact with South Korea's Daewoong Pharmaceutical Co Ltd to co-develop and commercialise a generic version of Leuprolide Acetate for depot suspension used to treat advanced prostatic cancer, endometriosis and uterine leiomyomata (fibroids).